The second commonest indication was cardiac surgery ( 201 doses , 10 % of the total ) followed by non-haematological oncology ( 127 doses , 6.5 % ) , critical care ( 106 doses , 5 % ) and liver disease ( 50 doses , 2.5 % ) .